Hybio Pharmaceutical (300199)

Hybio Pharmaceutical (300199)

$ 10

Trading Risk Analysis

English Version

Date : 1 Jan 2021


Hybio Pharmaceutical Co., Ltd. is a China-based company principally involved in the development, manufacture and distribution of chemical synthetic polypeptide pharmaceuticals. The Company?s products include polypeptide preparations, polypeptide active pharmaceutical ingredients (APIs) and customer polypeptide, among which the preparation products include thymopentin for injection, somatostatin for injection, desmopressin for injection and terlipressin for injection, among others. Through its subsidiaries, the Company’s newly added products are pharmaceutical packaging products, medical devices and solid products. The Company is also engaged in provision of related technological services.


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

You may also like…

Close Bitnami banner